Diabetic Neuropathic Pain Clinical Trial
Official title:
Genetics of Diabetes Audit and Research in Tayside Scotland (DOLORisk Dundee)
In 1997, the global prevalence of diabetes was estimated to be 125 million and this has risen to around 400 million in 2015. In addition diabetes has a number of complications including heart disease, blindness, kidney failure and amputation. This represents a significant burden on healthcare services. Type 2 diabetes (T2D) is caused by a combination of genetic and environmental factors. The aim of GoDARTS is to recruit participants with T2D to a registry to provide a platform with which to investigate the genetics of T2D, its complications and response to treatment. This study will investigate the genetic basis of diabetic neuropathic pain.
GoDARTS is the genetics arm of the DARTS study, which was set up to identify all diabetes patients in the Tayside region. Its aim is to improve diabetes care over and above existing practices. Participants are invited to attend to provide blood samples for DNA/RNA analysis, provide baseline anthropometric, biochemical, blood pressure and heart rate measurements as well as completing a lifestyle questionnaire containing smoking, menopausal and physical activity items. Consent is also obtained to allow anonymous linkage to electronic medical records (EMR) through use of the Community Health Index (CHI) number, a unique patient identifier that is issued to everyone registered with a general practitioner in Scotland. GoDARTS is the first EMR linked cohort in the world and provides access to individual participant longitudinal data including biochemical, comorbidity and prescription records. These are live databases and are constantly being updated. This allows for the study of genetic factors influencing T2D, its comorbidities and response to therapy. Consent has also been obtained for re-contact by collaborators, allowing for further studies of related phenotypes to take place. One of these studies is DOLORisk Dundee which aims to identify genetic and environmental risk factors for neuropathic pain. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05563454 -
A Study to Learn How Safe the Study Treatment BAY2395840 is, How it Affects the Body and How it Moves Into, Through, and Out of the Body if Given in Single and in Repetitive Doses to Japanese Healthy Male Participants
|
Phase 1 | |
| Not yet recruiting |
NCT04137328 -
Clinical Study on the Improvement of Diabetic Neuropathic Pain by Liraglutide
|
N/A | |
| Completed |
NCT00548925 -
A Safety and Efficacy Study in Subjects With Diabetic Neuropathic Pain
|
Phase 2 | |
| Completed |
NCT00452777 -
Efficacy and Tolerability of Novel A2A Agonist in Treatment of Diabetic Neuropathic Pain
|
Phase 2 | |
| Withdrawn |
NCT05406219 -
A Study to Learn How the Study Treatment BAY2395840 Moves Into, Through and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Moderate Reduced Kidney Function and in Healthy Male and Female Participants With Normal Kidney Function
|
Phase 1 | |
| Active, not recruiting |
NCT05351801 -
Proof of Concept Trial of Cannabis Derivatives in Neuropathic Pain
|
Phase 2 | |
| Completed |
NCT04454424 -
Study on the Safety of BAY1817080, How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug in Participants With Impaired Liver Function or Normal Liver Function
|
Phase 1 | |
| Recruiting |
NCT05986292 -
A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain
|
Phase 2 | |
| Terminated |
NCT00619983 -
Three Way Interaction Between Gabapentin, Duloxetine, and Donepezil in Patients With Diabetic Neuropathy
|
Phase 4 | |
| Completed |
NCT04265781 -
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
|
Phase 1 | |
| Completed |
NCT06336486 -
the Effectiveness of Intermittent Pneumatic Compression on Neuropathic Pain in Patients With Diabetic Polyneuropathy
|
N/A | |
| Completed |
NCT04487431 -
A Trial to Learn How a New Liquid Form of BAY1817080 is Tolerated and Taken up by the Body of Healthy Male Participants (Part A). By Labeling BAY1817080 With a Radioactive Substance (Carbon 14) Researchers Want to Learn How the Study Drug is Processed and Excreted by the Body After Dosing (Part B)
|
Phase 1 | |
| Completed |
NCT04471337 -
Study on the Safety of BAY1817080 How it is Tolerated and the Way the Body Absorbs, Distributes and Gets Rid of the Study Drug Given to Participants With Moderate Renal Impairment and End Stage Renal Disease Requiring Dialysis Compared With Matched Participants With Normal Renal Function
|
Phase 1 | |
| Completed |
NCT01589432 -
A Randomized, Double-blind, Placebo- and Active-controlled Study of the Electric Current Effects of ABT-639 on the Spontaneous Activity of Pain Sensory Receptors in Patients With Diabetic Peripheral Neuropathy
|
Phase 2 | |
| Terminated |
NCT01579279 -
A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain
|
Phase 2 | |
| Completed |
NCT01345045 -
A Multicenter Study Comparing the Analgesic Effects and Safety of ABT-639 Compared to Placebo in Subjects With Diabetic Neuropathic Pain
|
Phase 2 |